Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925274 | 0.86 | ALDH1A1 (0.54) | ALDH1A1TDP1MAPTCLCN2CDC25B | |
| SCHEMBL312482 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TDP1MAPTCLCN2KDM4E | |
| SCHEMBL314560 | 0.84 | GAA (0.53) | ALDH1A1MAPTCLCN2KDM4EHPGD | |
| SCHEMBL30949565 | 0.83 | TDP1 (0.55) | ALDH1A1TDP1MAPTCLCN2CDC25B | |
| SCHEMBL1203086 | 0.83 | ALDH1A1 (0.59) | ALDH1A1TDP1MAPTCDC25BKDM4E | |
| SCHEMBL6931814 | 0.83 | TDP1 (0.55) | ALDH1A1TDP1MAPTCLCN2CDC25B | |
| SCHEMBL2617466 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1MAPTMAPK1KMT2A | |
| SCHEMBL27972201 | 0.81 | HMGCR (0.46) | ALDH1A1KDM4ECA9MAPK1KMT2A | |
| SCHEMBL2837874 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPTCDC25BKDM4E | |
| SCHEMBL17201318 | 0.80 | MAPT (0.66) | ALDH1A1TDP1MAPTCLCN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925100-A | Substituted thiophenoquinolinone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3126354-B1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-01-22 | — | — | EP | disclosed |
| CN-109999039-A | Quinazoline-THF- the amine of halogenation as PDE1 inhibitor | H.隆德贝克有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-20190144434-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| CN-106132953-B | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H.隆德贝克有限公司 | 2019-03-22 | — | — | CN | disclosed |
| US-10005764-B2 | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-06-26 | — | — | US | disclosed |
| EP-3126354-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022186-A1 | Halogenated Quinazolin-THF-Amines as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| CN-106132953-A | Halogenated quinazolin-THF-amines as PDE1 inhibitors | H.隆德贝克有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-2250174-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144434-A1 | HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS | PDE12, PDE3A, PDE7B | ALDH1A1 179/4885TDP1 10/4885MAPT 464/4885 |
| US-10005764-B2 | Halogenated quinazolin-THF-amines as PDE1 inhibitors | PDE12, PDE3A, PDE7B | ALDH1A1 179/4885TDP1 10/4885MAPT 464/4885 |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | ALDH1A1 1790/4885TDP1 3951/4885MAPT 3005/4885 |
| US-20170022186-A1 | Halogenated Quinazolin-THF-Amines as PDE1 Inhibitors | PDE12, PDE3A, PDE7B | ALDH1A1 179/4885TDP1 10/4885MAPT 464/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | ALDH1A1 1790/4885TDP1 3951/4885MAPT 3005/4885 |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | ALDH1A1 1913/4885TDP1 4094/4885MAPT 3077/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | ALDH1A1 1913/4885TDP1 4094/4885MAPT 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.